BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease? Parkinsonism Relat Disord 2020;80 Suppl 1:S45-53. [PMID: 33349580 DOI: 10.1016/j.parkreldis.2020.10.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Crotty GF, Schwarzschild MA. What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs. Neurology 2022;99:34-41. [PMID: 35970592 DOI: 10.1212/WNL.0000000000200238] [Reference Citation Analysis]
2 Volf NV, Privodnova EY. Habitual Coffee Consumption Alters Attention and Memory in Older Adults: Significance of Intellectual Workload. Hum Physiol 2022;48:299-305. [DOI: 10.1134/s0362119722030124] [Reference Citation Analysis]
3 Reichmann H, Csoti I, Koschel J, Lorenzl S, Schrader C, Winkler J, Wüllner U. Life style and Parkinson's disease. J Neural Transm (Vienna) 2022. [PMID: 35606622 DOI: 10.1007/s00702-022-02509-1] [Reference Citation Analysis]
4 Reichmann H. [Caffeine, Chocolate and Adenosine A2A Receptor Antagonists in the Treatment of Parkinson's Disease]. Fortschr Neurol Psychiatr 2022. [PMID: 35584767 DOI: 10.1055/a-1785-3632] [Reference Citation Analysis]
5 Saimaiti A, Zhou DD, Li J, Xiong RG, Gan RY, Huang SY, Shang A, Zhao CN, Li HY, Li HB. Dietary sources, health benefits, and risks of caffeine. Crit Rev Food Sci Nutr 2022;:1-19. [PMID: 35574653 DOI: 10.1080/10408398.2022.2074362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Mori A, Chen JF, Uchida S, Durlach C, King SM, Jenner P. The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease. Molecules 2022;27:2366. [PMID: 35408767 DOI: 10.3390/molecules27072366] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Angela Cenci M, Skovgård K, Odin P. Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease. Neuropharmacology 2022. [DOI: 10.1016/j.neuropharm.2022.109027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Merighi S, Borea PA, Varani K, Vincenzi F, Jacobson KA, Gessi S. A(2A) Adenosine Receptor Antagonists in Neurodegenerative Diseases. Curr Med Chem 2022;29:4138-51. [PMID: 34844537 DOI: 10.2174/0929867328666211129122550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Mori A, Cross B, Uchida S, Kerrick Walker J, Ristuccia R. How Are Adenosine and Adenosine A2A Receptors Involved in the Pathophysiology of Amyotrophic Lateral Sclerosis? Biomedicines 2021;9:1027. [PMID: 34440231 DOI: 10.3390/biomedicines9081027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 . Selected Literature Watch. Journal of Caffeine and Adenosine Research 2021;11:23-4. [DOI: 10.1089/caff.2021.29019.slw] [Reference Citation Analysis]
11 Jenner P, Mori A, Aradi SD, Hauser RA. Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson's disease. Expert Rev Neurother 2021;21:317-33. [PMID: 33507105 DOI: 10.1080/14737175.2021.1880896] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]